Mr. Slavin is the founding CEO of Fuzionaire and Fuzionaire Theranostics. His mission is to create a better and more hopeful future. Through the work of Fuzionaire, he is leveraging the power of scientific breakthroughs to solve some of the world’s biggest challenges at scale. Outside of Fuzionaire, Mr. Slavin is the founder and chairman of the Slavin Family Foundation, whose fellowships support some of the world’s top student entrepreneurs, and the founder of EES Ventures, a seed-stage venture capital firm. With Nova Spivack, Mr. Slavin is also a co-founder of the Arch Mission Foundation (AMF), a nonprofit creating repositories of human knowledge and biology in space. AMF launched the first permanent library in solar-orbit in February 2018 in the glove box of Elon Musk’s Tesla Roaster, which was the payload for SpaceX’s Falcon Heavy test flight. In 2019, AMF landed the Lunar Library on the Moon. Previously, Mr. Slavin spent six years at top-ranked law firm Skadden Arps, focusing on public and private mergers and acquisitions. He hold a BA from Yale, magna cum laude and Phi Beta Kappa, where he founded his first company and graduated at 19, and a JD from Harvard Law School.

LinkedIn

Dr. Waldmann is a radiopharmacist and scientist with more than a decade of experience in radiopharmaceutical manufacturing and development. Prior to joining Fuzionaire Theranostics, Dr. Waldmann was the Head of Radiochemistry at the University Medical Center Mainz, where he established a GMP-radiopharmacy to supply the nuclear medicine department with theranostic radiopharmaceuticals. He continues to be an advisor to the University Medical Center and holds a scientific affiliation there.

Previously, Dr. Waldmann was a postdoctoral researcher at UCLA’s Crump Institute for Molecular Imaging, a leading radiopharmaceutical institution led by the inventor of the PET scanner, Prof. Michael E. Phelps. At UCLA, Dr. Waldmann invented the HetSiFA® technology in collaboration with the laboratory of Nobel Laureate Robert H. Grubbs at Caltech. He is the first inventor of the seminal HetSiFA patent and shares inventorship with the late Dr. Grubbs. The invention constitutes the scientific basis of Fuzionaire Theranostics. As a radiochemist at UCLA’s Ahmanson Translational Imaging Division, Dr. Waldmann was committed to the GMP production of radiopharmaceuticals for clinical trials. Dr. Waldmann holds a Ph.D. in PET radiochemistry from the University of Münster, Germany, where he was mentored by Prof. Klaus Kopka, a pioneer in the field of nuclear medicine theranostics and known for the original development of Novartis’s Pluvicto. He is the author of a chapter on ¹⁸F PET tracers in the textbook Molecular Imaging in Oncology, and his work has been published in leading academic journals, including Theranostics, PNAS, and Nature.